Business Description
Orchid Pharma Ltd
ISIN : US68572Y2090
Share Class Description:
LUX:ORCHP: DRTotal Employee Number:
1,051Compare
Compare
Traded in other countries / regions
524372.IndiaORCHP.Luxembourg IPO Date
2005-11-03Description
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | 5.2 | |||||
Interest Coverage | 6.23 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 5.44 | |||||
Beneish M-Score | -2.01 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.7 | |||||
3-Year EBITDA Growth Rate | -26.7 | |||||
3-Year EPS without NRI Growth Rate | 14.6 | |||||
3-Year FCF Growth Rate | -50.6 | |||||
3-Year Book Growth Rate | 14.6 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.45 | |||||
Quick Ratio | 1.53 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 176.02 | |||||
Days Sales Outstanding | 106.15 | |||||
Days Payable | 139.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.5 | |||||
Shareholder Yield % | -3.12 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 35.18 | |||||
Operating Margin % | 10.18 | |||||
Net Margin % | 2.51 | |||||
EBITDA Margin % | 8.59 | |||||
FCF Margin % | -33.55 | |||||
OCF Margin % | 12.03 | |||||
ROE % | 1.59 | |||||
ROA % | 1.15 | |||||
ROIC % | 5.56 | |||||
3-Year ROIIC % | 22.14 | |||||
ROC (Joel Greenblatt) % | 2.75 | |||||
ROCE % | 2.26 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 240.14 | |||||
Forward PE Ratio | 28.99 | |||||
PE Ratio without NRI | 189.86 | |||||
PEG Ratio | 67.81 | |||||
PS Ratio | 6.02 | |||||
PB Ratio | 3.79 | |||||
Price-to-Tangible-Book | 4.04 | |||||
Price-to-Operating-Cash-Flow | 48.28 | |||||
EV-to-EBIT | 150.62 | |||||
EV-to-EBITDA | 74.04 | |||||
EV-to-Revenue | 6.36 | |||||
EV-to-FCF | -18.28 | |||||
Price-to-GF-Value | 1.18 | |||||
Price-to-Projected-FCF | 9.4 | |||||
Price-to-Peter-Lynch-Fair-Value | 19.46 | |||||
Price-to-Graham-Number | 5.8 | |||||
| Price-to-Net-Current-Asset-Value | 77.86 | |||||
Earnings Yield (Greenblatt) % | 0.66 | |||||
FCF Yield % | -5.78 | |||||
Forward Rate of Return (Yacktman) % | 1.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Orchid Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 90.668 | ||
| EPS (TTM) ($) | 0.044 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -53.22 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 5.45 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 5.45 - 5.45 | ||
| Shares Outstanding (Mil) | 50.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Orchid Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Orchid Pharma Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.004587:1 Stock Split | 2020-11-09 | 61.48 (+0.71%) |
Show
Entries
Orchid Pharma Ltd Frequently Asked Questions
What is Orchid Pharma Ltd(LUX:ORCHP)'s stock price today?
The current price of LUX:ORCHP is $5.45. The 52 week high of LUX:ORCHP is $5.45 and 52 week low is $5.45.
When is next earnings date of Orchid Pharma Ltd(LUX:ORCHP)?
The next earnings date of Orchid Pharma Ltd(LUX:ORCHP) is .
Does Orchid Pharma Ltd(LUX:ORCHP) pay dividends? If so, how much?
Orchid Pharma Ltd(LUX:ORCHP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Orchid Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers